Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID-I: Infliximab in Acute Pancreatitis
NCT03684278Phase 2Recruiting
- Sponsor
- University of Liverpool
- Start
- May 2019
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of infliximab in acute pancreatitis (AP) (3 arms), sponsored by University of Liverpool. Primary endpoint: C-Reactive Protein at Day 14. Started May 2019; status: recruiting.
02
Drugs
infliximab
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT03684278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684278.